Submissions for variant NM_020547.3(AMHR2):c.1510C>T (p.Arg504Cys)

Total submissions: 1

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV003331639	SCV004038583	pathogenic	Persistent Mullerian duct syndrome	2023-08-02	criteria provided, single submitter	clinical testing	Variant summary: AMHR2 c.1510C>T (p.Arg504Cys) results in a non-conservative amino acid change located in the protein kinase domain (IPR000719) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251426 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1510C>T has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Persistent Mullerian duct syndrome (e.g., Imbeaud_1996, Avolio_2003, Picard_2017, Bugrul_2019, Unal_2021). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant protein was unable to mediate AMH activation of Smad1 in vitro (e.g., Belville_2009). The following publications have been ascertained in the context of this evaluation (PMID: 19457927, 32961540, 8872466, 28528332, 33025551, 12893352). No submitters have reported clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.